Lifecore Biomedical Inc (LFCR)
5.68
-0.15
(-2.57%)
USD |
NASDAQ |
May 23, 16:00
5.68
0.00 (0.00%)
After-Hours: 17:00
Lifecore Biomedical Research and Development Expense (Quarterly): 2.116M for May 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2023 | 2.608M |
| February 28, 2023 | 1.964M |
| November 30, 2022 | 2.118M |
| August 31, 2022 | 2.048M |
| May 31, 2022 | 2.117M |
| February 28, 2022 | 2.00M |
| November 30, 2021 | 1.856M |
| August 31, 2021 | 1.873M |
| May 31, 2021 | 1.161M |
| February 28, 2021 | 1.843M |
| November 30, 2020 | 2.572M |
| August 31, 2020 | 2.508M |
| May 31, 2020 | -0.808M |
| February 29, 2020 | 2.747M |
| November 30, 2019 | 2.822M |
| August 31, 2019 | 2.821M |
| May 31, 2019 | 3.461M |
| February 28, 2019 | 2.739M |
| November 30, 2018 | 2.475M |
| August 31, 2018 | 2.791M |
| May 31, 2018 | 3.596M |
| February 28, 2018 | 3.113M |
| November 30, 2017 | 3.372M |
| August 31, 2017 | 2.719M |
| May 31, 2017 | 3.556M |
| Date | Value |
|---|---|
| February 28, 2017 | 2.014M |
| November 30, 2016 | 1.965M |
| August 31, 2016 | 1.938M |
| May 31, 2016 | 1.815M |
| February 29, 2016 | 1.895M |
| November 30, 2015 | 1.643M |
| August 31, 2015 | 1.875M |
| May 31, 2015 | 1.613M |
| February 28, 2015 | 1.755M |
| November 30, 2014 | 1.825M |
| August 31, 2014 | 1.795M |
| May 31, 2014 | 1.636M |
| February 28, 2014 | 1.723M |
| November 30, 2013 | 1.919M |
| August 31, 2013 | 1.926M |
| May 31, 2013 | 2.652M |
| February 28, 2013 | 2.325M |
| November 30, 2012 | 2.113M |
| August 31, 2012 | 2.204M |
| May 31, 2012 | 2.483M |
| February 29, 2012 | 2.473M |
| November 30, 2011 | 2.337M |
| August 31, 2011 | 2.333M |
| May 31, 2011 | 2.513M |
| February 28, 2011 | 2.275M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-0.808M
Minimum
May 2020
3.461M
Maximum
May 2019
2.101M
Average
2.117M
Median
May 2022
Research and Development Expense (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 5.932M |
| SELLAS Life Sciences Group Inc | 5.111M |
| ADMA Biologics Inc | 0.45M |
| Relmada Therapeutics Inc | 13.31M |
| Jaguar Health Inc | 4.312M |